Bellberry Limited, Australia’s largest reviewer of human research is celebrating its 20th year of operations. The company is an independent not-for-profit organisation providing research ethics services across Australia.

Bellberry is driven by two key objectives, to protect the welfare of research participants and to improve the quality, efficiency and effectiveness of research. It provides high-quality, time efficient and internationally accredited scientific and ethical review of research projects.

Bellberry provides specialist ethical oversight to almost 40% of clinical trials registered to the Therapeutic Goods Administration (TGA), which is the Australian equivalent of the FDA in the US or the EMA in Europe.

Starting with one Human Research Ethics Committee (HREC) in 2004, 20 years later Bellberry has 12 HRECs operating with 150 members undertaking reviews across all phases of clinical and device trials as well as social and behavioural studies.

Bellberry is at the forefront of global drug development, and is the first organisation in Australia to achieve international accreditation for excellence and ethically sound processes in running HRECs by the Association for the Accreditation of Human Research Protection Programs (AAHRPP).

Bellberry reinvests all its surplus funds back into the Australian medical research sector.

Bellberry’s Director of Operations, Jerneen Williams, and Director of Strategic Projects, Trina O’Donnell, will be attending BIO Korea.

For media inquiries please contact Alison Rogers alisonrogers@bellberry.com.au